Drugs / RMC-5552
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05557292 | Apr 2023 → Dec 2025 | glioblastoma | Nicholas Butowski | Terminated | No outcome recorded |
| Phase 1 | NCT04774952 | Apr 2021 → May 2024 | cancer | Revolution Medicines, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-12-19 | Revolution Medicines, Inc. | Results Revolution Medicines Announces Publication Describing Design and Synthesis of RMC-5552, a First-in-Class, Bi-Steric mTORC1-Selective Inhibitor revmed.com ↗
The manuscript describes the unprecedented compound profile that includes 40-fold selectivity for mTORC1 over mTORC2 and greater than 53-fold selectivity over other lipid kinases. |
| 2021-06-24 | Revolution Medicines, Inc. | Results Revolution Medicines Announces Publication of Scientific Paper Describing Novel Class of Anti-Tumor Compounds Targeting mTORC1 revmed.com ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-12-19 | Revolution Medicines, Inc. | Revolution Medicines Announces Publication Describing Design and Synthesis of RMC-5552, a First-in-Class, Bi-Steric mTORC1-Selective Inhibitor revmed.com ↗ |
| 2021-06-24 | Revolution Medicines, Inc. | Revolution Medicines Announces Publication of Scientific Paper Describing Novel Class of Anti-Tumor Compounds Targeting mTORC1 revmed.com ↗ |
| 2021-04-21 | Revolution Medicines, Inc. | Revolution Medicines Announces Dosing of First Patient in Phase 1/1b Clinical Study of RMC-5552 in Patients with Advanced Solid Tumors revmed.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RMC-5552 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05557292 ↗ |
| Action | Inhibit | “mTORC1-selective inhibitor that potently inhibits phosphorylation” PMID 41056387 ↗ Dec 2025 |
| Route | Intravenous | “RMC-5552 (1.6-16 mg intravenous infusion weekly)” PMID 41056387 ↗ Dec 2025 |
| Target | MTOR | “RMC-5552 is a bi-steric, mTOR complex 1 (mTORC1)-selective inhibitor” PMID 41056387 ↗ Dec 2025 |